I would like to think that the strategy is to have the...

I would like to think that the strategy is to have the additional trials in play before the results are announced later in the year to add value to shareholders should big pharma come sniffing.
If we only had the Ovarian Cancer trial in progress then we would be valued at only the one Cancer type. This opens up other potential pipelines that may even be fast tracked should CVac prove effective. This is an excellent move IMO, Even if the results are not as spectacular as some might hope there is now other trials in motion that compatible combination therapies could be applied too.

I remember a couple years back when this was just a dream.
Well done management you made it happen!
Go PRR!